Accordingly, the 2016 WHO classification of CNS tumors required the molecular analysis of a number of foci, including the isocitrate dehydrogenase (IDH) 1/2 gene and T53 mutation status, the 1p/19q codeletion, and the O6-methylguanine-DNA methyl-transferase (MGMT) gene methylation for proper classification of gliomas [2]. This evidence concerns the gene IDH3A and central nervous system cancer.